The purpose of the trial is to determine whether MK-8748 is at least as effective as aflibercept in preserving or improving vision. Participants will receive a series of injections into the eye over the course of about one year, with regular visits for eye checks, vision testing, and imaging that may involve the fluorescein dye.

Vision is measured using best-corrected visual acuity, which is the sharpest vision possible with the best glasses or contacts, and the results are recorded as letters on an ETDRS chart, a standard eye‑test chart. Throughout the study, doctors will monitor participants for any side effects or safety concerns.

The purpose of the trial is to determine whether the new drug works at least as well as the existing treatment in preserving or improving vision. Vision will be assessed using a standard test called Best-Corrected Visual Acuity, which measures how many letters a person can read on an eye chart, reported in ETDRS letters.

Participants will receive a series of eye injections over roughly one year, with regular visits to check eye health, vision scores, and any side effects. The study is designed so that neither the participants nor the doctors know which medication is being given at each visit.

The purpose of this research is to evaluate how well the Port Delivery System works when the medicine is refilled every 36 weeks. The medication being studied, ranibizumab, is already approved for treating wet AMD when given as regular eye injections. In this study, participants will receive the implanted delivery system and will have it refilled with medication according to a set schedule over approximately 72 weeks.

During the study, patients will have regular eye examinations and vision tests to monitor their condition. The Port Delivery System will be surgically implanted into the eye at the beginning of the study, and then the medicine will be refilled through this system. The study will compare this new delivery method to traditional eye injections and will monitor both the effectiveness of the treatment and any side effects that may occur.

The purpose of the study is to explore how automated tools can help in assessing and treating patients with active neovascular AMD in a real-world setting. This approach aims to benefit both patients and the healthcare system by potentially reducing the number of visits and treatments needed. Participants in the study will receive one of the medications and will be monitored over a period of time to see how well the treatment works in managing their condition.

Throughout the study, various aspects of the eye’s health will be assessed, including visual acuity, which is how well one can see, and changes in the structure of the eye, such as the thickness of the retina and the presence of fluid. The study will also look at the overall quality of life of participants, as well as any changes in the eye’s blood flow and the formation of any new eye conditions. The study is expected to continue until 2025.

The purpose of the study is to evaluate how these treatments affect the growth of lesions, or damaged areas, in the eye over a period of 52 weeks. Participants will receive either Pozelimab in combination with Cemdisiran, Cemdisiran alone, or a placebo. The study will involve regular visits to the clinic for injections and monitoring of eye health. Participants will undergo various tests to assess changes in their vision and the size of the lesions in their eyes.

This trial aims to provide valuable information on the safety and effectiveness of these treatments for individuals with Geographic Atrophy due to Age-Related Macular Degeneration. The study will help determine if these medications can slow down the progression of the disease and improve or maintain vision in affected individuals.

Participants in the study will receive the treatment through an implantation procedure. The study will last for a period of time, during which participants will have regular check-ups to monitor their vision and overall health. The study will compare the changes in vision between the two refill schedules to determine which is more beneficial for patients with nAMD.

Throughout the study, participants will be monitored for any side effects or changes in their condition. The study aims to provide valuable information on the best way to manage nAMD using the Port Delivery System with ranibizumab, potentially offering a new option for those affected by this eye disease.

The purpose of the study is to investigate how effective two initial doses of faricimab are in reducing disease activity in patients who have not received treatment for neovascular AMD before. Participants will receive these doses through an injection into the eye, a method known as intravitreal use. The study will monitor the patients over a period to see if the disease becomes less active and to assess any changes in vision and eye health.

Throughout the study, researchers will evaluate the proportion of patients who show no signs of disease activity after eight weeks. They will also look at how often patients need further treatment after the initial doses and any changes in vision clarity and eye structure. This information will help determine the effectiveness of the treatment and provide insights into managing neovascular AMD more effectively.

The purpose of the study is to evaluate how well this imaging technique can show the effects of treatment in patients with AMD. Participants will receive intraocular antiangiogenic injections, which are treatments that help reduce abnormal blood vessel growth in the eye. The study will observe the patients over a period of three months to see how their eyes respond to the treatment.

Throughout the study, the imaging technique will be used to compare the affected eye with the unaffected eye. This will help researchers understand the relationship between the imaging results and changes in the eye’s structure and vision. The study aims to provide valuable insights into the effectiveness of the treatment and the potential of the imaging method in monitoring AMD.

Participants in the study will receive either Ranibizumab or Bevacizumab through an injection into the eye, a method known as intravitreal use. The study will last for about a year, during which time participants will have regular check-ups to monitor their vision and overall health. Saliva samples will be collected to study genetic factors that might affect treatment response. This involves looking at specific genes that could play a role in how well the treatments work for different individuals.

The study is designed to be double-blind, meaning neither the participants nor the researchers will know which treatment is being given to ensure unbiased results. By the end of the study, researchers hope to better understand the effectiveness of these treatments and the role of genetic factors in treating Age-Related Macular Degeneration.